ARTICLE | Clinical News
TNX-102 SL: Ph II AtEase data
January 27, 2017 9:37 PM UTC
The double-blind, U.S Phase II AtEase trial in 231 patients with military-related PTSD showed that once-daily 2.8 mg sublingual TNX-102 SL given at bedtime missed the primary endpoint of improving CAP...
BCIQ Company Profiles